Brief: Rani Therapeutics Announces New RT-111 Development Program

Rani Therapeutics Holdings

24/10/2022 13:42

Oct 24 (Reuters) - Rani Therapeutics Holdings Inc
 RANI.O :
    * RANI THERAPEUTICS ANNOUNCES NEW RT-111 DEVELOPMENT PROGRAM
AND
PROVIDES CORPORATE UPDATE
    * RANI THERAPEUTICS ANNOUNCES NEW RT-111 DEVELOPMENT PROGRAM
AND
PROVIDES CORPORATE UPDATE
    * RANI THERAPEUTICS HOLDINGS INC - RT-102 PHASE 1
REPEAT-DOSE
TOPLINE DATA ANTICIPATED IN 4Q 2022
    * RANI THERAPEUTICS HOLDINGS INC - INITIATION OF IN VIVO
STUDIES
WITH FULLY-AUTONOMOUS RANIPILL HC ANTICIPATED IN 4Q 2022
    * RANI THERAPEUTICS HOLDINGS INC - IN 2023, INTENDS TO
INITIATE
PHASE 2 STUDY WITH RT-102, TO COMMENCE PHASE 1 STUDIES WITH
THREE PIPELINE MOLECULES

Source text for Eikon:  ID:nGNX507Sd4 
Further company coverage:  RANI.O 
 ((Reuters.Briefs@thomsonreuters.com;))